The Innovative Medicines Initiative (IMI) is a proposed partnership between the European Commission and the European Federation of Pharmaceutical Industry and Associations. Its objective is to lead and reinvigorate research and development within the European bio-pharmaceutical industry and, in the long term, to provide faster access to better medicines for EU citizens. This goal will be realised through the provision of funding to European Public-Private Collaborations, consisting of academic institutions, SMEs, bio-pharmaceutical companies, regulatory authorities and patients. The proposed budget will comprise a contribution of EUR 1 billion from the European Union’s 7th Research Framework Programme for the period 2007 – 2013, matched by the provision of research and development resources from the bio-pharmaceutical industry. (See Brussels Brief of 20 April 2007).